Loading...
XPAR
TNG
Market cap141mUSD
Dec 05, Last price  
0.92EUR
1D
5.77%
1Q
-16.73%
Jan 2017
-64.94%
Name

Transgene SA

Chart & Performance

D1W1MN
XPAR:TNG chart
P/E
—
P/S
396.52
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.02%
Rev. gr., 5y
-45.94%
Revenues
307k
-74.07%
2,514,0005,546,00028,019,00013,949,00011,765,00014,112,00014,446,0003,928,0003,849,0002,490,0001,465,0002,346,0002,099,0001,335,0006,652,0002,981,0009,993,0003,126,0001,184,000307,000
Net income
-34m
L+52.15%
-20,485,000-22,031,000-5,521,000-18,000,000-27,347,000-34,219,000-43,626,000-43,203,000-42,858,000-48,556,000-46,374,000-25,207,000-32,274,0008,026,000-21,360,000-18,450,000-20,004,000-32,810,000-22,328,000-33,971,000
CFO
-24m
L-32.08%
-19,109,000-19,538,000-2,073,000-23,387,000-18,720,000-24,929,000-44,162,000-51,294,000-50,185,000-54,236,000-45,152,000-33,585,000-35,370,000-28,381,000-22,413,000-28,742,000-31,943,000-20,303,000-34,671,000-23,548,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
URL
https://www.transgene.fr
IPO date
Mar 25, 1998
Employees
146
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT